Evans R M, Doelle G C, Lindner J, Bradley V, Rabin D
J Clin Invest. 1984 Jan;73(1):262-6. doi: 10.1172/JCI111200.
The effect of the luteinizing hormone-releasing hormone (LHRH) agonist, [D-Trp6,Pro9-NEth]LHRH (LHRHA), on luteinizing hormone (LH) bioactivity was assessed with a rat interstitial cell assay in four men during a 14-d treatment period. Biologic/immunologic (B/I) ratios were unchanged initially with treatment but by day 12 had fallen to levels lower than basal values. Frequent sampling on day 12 revealed blunted gonadotropin responsiveness to LHRHA and absence of spontaneous LH pulsations. Despite continued administration of LHRHA, human chorionic gonadotropin administration resulted in elevated B/I ratios and testosterone levels. Further characterization of the serum immunoreactive LH by Sephadex chromatography revealed a later elution profile during treatment with LHRHA. Thus, LHRHA appears to act, in part, by modification of the bioactivity of LH in man.
在为期14天的治疗期间,采用大鼠间质细胞试验评估了促黄体生成激素释放激素(LHRH)激动剂[D-色氨酸6,脯氨酸9-乙基]LHRH(LHRHA)对4名男性促黄体生成激素(LH)生物活性的影响。生物/免疫(B/I)比值在治疗初期未发生变化,但到第12天时已降至低于基础值的水平。在第12天频繁采样显示,促性腺激素对LHRHA的反应减弱,且无自发性LH脉冲。尽管持续给予LHRHA,但注射人绒毛膜促性腺激素会导致B/I比值和睾酮水平升高。通过Sephadex层析对血清免疫反应性LH进行进一步表征,结果显示在LHRHA治疗期间其洗脱谱延迟。因此,LHRHA似乎部分通过改变人体内LH的生物活性发挥作用。